Date of Call: Thursday, January 31, 2013 Time of Call: 10 a.m. EST Participant Operator Assisted Toll-Free Dial-In Number: (877) 312-5845 Participant Operator Assisted International Dial-In Number: (970) 315-0470The purpose of the call is to provide the Company's stockholders with a review of recent Company activity and management's go-forward plans. The discussion will include: the clinical and regulatory status of the AE37 breast cancer vaccine and business development initiatives; the clinical and regulatory status of the Generex Oral-lyn™ buccal insulin spray product; the status of the proposed spinout of Antigen Express; Company finances; and, the annual and special meeting of the Company's stockholders (scheduled for March 28, 2013). Participating in the call on behalf of the Company will be:
- Mark Fletcher, President & Chief Executive Officer
- John Barratt, Chairman of the Board
- Dr. Eric von Hofe, President of Antigen Express, Inc.
- Dr. James H. Anderson, Jr., Director and Senior Scientific Advisor
- Dr. David Brusegard, Chief Operating Officer